Shopping Cart
Remove All
Your shopping cart is currently empty
Ozoralizumab (Synonyms: TS-152, ATN-103)
Catalog No. T77126 Copy Product Info
🥰Excellent
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.
Ozoralizumab
Copy Product Info🥰Excellent
Catalog No. T77126
Synonyms TS-152, ATN-103
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.
Ozoralizumab
Cas No. 1167985-17-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | In Stock | In Stock | |
| 5 mg | $859 | In Stock | In Stock | |
| 10 mg | $1,270 | In Stock | In Stock | |
| 25 mg | $1,890 | - | In Stock | |
| 50 mg | $2,550 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis. |
| In vitro | METHODS: Ozoralizumab (ATN-103) (0.1-1000pM) was used to treat L929 cells and its high TNFα neutralizing potency was determined. RESULTS: Ozoralizumab (ATN-103) has high TNFα neutralizing potency, with very similar binding and dissociation properties, and KD values for human TNFα and monkey TNFα are 20.2 pM and 16.1 pM, respectively. [1] |
| In vivo | METHODS: Tg197 mice were injected subcutaneously with 1 mg/kg dose of Ozoralizumab (ATN-103) twice weekly to evaluate the formation of ADA against each anti-TNFα antibody and the effect of long-term administration of these anti-TNFα antibodies on TNFα-mediated TNFα in Tg197 mice. Efficacy of polyarthritis. RESULTS: Ozoralizumab (ATN-103) significantly and comparably reduced arthritis scores. [1] |
| Synonyms | TS-152, ATN-103 |
| Reactivity | Human |
| Verified Activity | Immobilized Human TNFa Protein at 2 μg/mL can bind Ozoralizumab (VHH). The EC50 is 0.004992 μg/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFSF2/TNFa |
| Molecular Weight | 38.44 kDa |
| Cas No. | 1167985-17-2 |
| Isotype | VHH1-VHH2-VHH1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Ozoralizumab | purchase Ozoralizumab | Ozoralizumab cost | order Ozoralizumab | Ozoralizumab in vivo | Ozoralizumab in vitro | Ozoralizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.